Perilla seed oil improves bone health by inhibiting bone resorption in healthy Japanese adults: A 12-month, randomized, double-blind, placebo-controlled trial.
- 2023-01-13
- Phytotherapy research : PTR 37(6)
- Kentaro Matsuzaki
- Shahdat Hossain
- Harumi Wakatsuki
- Yoko Tanabe
- Miho Ohno
- Setsushi Kato
- Osamu Shido
- Michio Hashimoto
- PubMed: 36637040
- DOI: 10.1002/ptr.7728
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 52
- Population
- 52 Japanese adults (mean age 54.2 ± 6.4 years)
- Methods
- Randomized, double-blind, placebo-controlled trial; 7.0 ml/day of perilla seed oil or olive oil for 12 months
- Blinding
- Double-blind
- Duration
- 12 months
- Funding
- Unclear
Accumulating evidence suggests the beneficial effect of omega-3 polyunsaturated fatty acids (PUFAs) on bone mineral density (BMD). However, the effects of perilla (Perilla frutescens) seed oil (PO), a rich source of α-linoleic acid (LNA), on human bone have not yet been elucidated. This randomized, double-blind, placebo-controlled trial investigated the effects of long-term PO intake on bone health in Japanese adults. After screening for eligibility, 52 participants (mean age 54.2 ± 6.4 years) were randomly assigned to placebo (n = 25) and PO (n = 27) groups, which received 7.0 ml of olive oil and PO daily, respectively. At baseline and 12-month, quantitative ultrasound of the right calcaneus was measured with an ultrasound bone densitometer and percentage of the Young Adult Mean (%YAM) was calculated. Serum levels of tartrate-resistant acid phosphatase 5b (TRACP-5b), and bone alkaline phosphatase (BALP) were evaluated. In addition, PUFA levels in the erythrocyte plasma membrane (RBC-PM), serum biological antioxidant potential (BAP), and diacron reactive oxygen metabolites (d-ROM) were evaluated. Compared with the placebo group, %YAM levels increased and serum TRACP-5b levels decreased significantly in the PO group at 12-month, while serum BALP levels remained unchanged. Moreover, RBC-PM LNA levels and BAP/d-ROM ratios increased significantly in the PO compared with the placebo group. These results suggest that long-term PO intake may improve age-related BMD decline by suppressing bone resorption and increasing LNA levels.
Research Insights
Compared with the placebo group, %YAM levels increased and serum TRACP-5b levels decreased significantly in the PO group at 12-month
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 7.0 ml/day
serum BALP levels remained unchanged
- Effect
- Neutral
- Effect size
- Small
- Dose
- 7.0 ml/day
Compared with the placebo group, %YAM levels increased and serum TRACP-5b levels decreased significantly in the PO group at 12-month
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 7.0 ml/day